Kytopen Corp.
Kytopen is a biotechnology company dedicated to accelerating the discovery, development, and manufacturing of gene-modified cell therapies through innovative, scalable, non-viral transfection platforms. Founded as an MIT spin-out, the company develops the proprietary Flowfect® technology, which combines microfluidics and automation to enable efficient, high-throughput gene delivery into cells, facilitating faster and more cost-effective cell therapy production. Kytopen's mission is to revolutionize gene delivery methods, making advanced cell therapies more accessible and scalable from discovery to manufacturing.
Industries
Nr. of Employees
small (1-50)
Products
Automated small-volume high-throughput transfection system
Automated small-volume liquid-handler integrated with continuous-flow transfection to run up to 96 conditions per experiment for discovery, screening, and process optimization (sample volumes 50–100 µL; run time ~10–15 minutes).
Closed-system large-scale transfection system
Closed-system instrument for manufacturing-scale continuous-flow transfection able to process high cell concentrations and a wide range of volumes to support clinical manufacturing workflows.
Transfection consumables and buffers
Single-use consumables and buffer formulations sized for small-, medium- and large-volume transfections, including single-use tips, medium- and large-volume cartridges, and formulated transfection buffer products.
Cloud-based profile designer and downloads
Web portal and profile designer for creating, encrypting, and distributing platform delivery profiles and for downloading IFUs, operating manuals, plate templates, and software updates.
Automated small-volume high-throughput transfection system
Automated small-volume liquid-handler integrated with continuous-flow transfection to run up to 96 conditions per experiment for discovery, screening, and process optimization (sample volumes 50–100 µL; run time ~10–15 minutes).
Closed-system large-scale transfection system
Closed-system instrument for manufacturing-scale continuous-flow transfection able to process high cell concentrations and a wide range of volumes to support clinical manufacturing workflows.
Transfection consumables and buffers
Single-use consumables and buffer formulations sized for small-, medium- and large-volume transfections, including single-use tips, medium- and large-volume cartridges, and formulated transfection buffer products.
Cloud-based profile designer and downloads
Web portal and profile designer for creating, encrypting, and distributing platform delivery profiles and for downloading IFUs, operating manuals, plate templates, and software updates.
Services
Multi-month partner program to validate technical needs, demonstrate platform capabilities, optimize delivery profiles, and transfer partner processes to the platform with staged milestones over six months.
Multi-month partner program to validate technical needs, demonstrate platform capabilities, optimize delivery profiles, and transfer partner processes to the platform with staged milestones over six months.
Expertise Areas
- Non-viral gene delivery for cell therapies
- High-throughput transfection screening and optimization
- Cell therapy process development and scale-up
- Technology transfer and process validation
Key Technologies
- Continuous-flow electroporation
- Non-viral nucleic acid and RNP delivery
- Automated small-volume liquid-handling for transfection
- Closed-system large-volume transfection
News & Updates
Kytopen appoints new board of directors as part of its commercial expansion of the Flowfect Tx® platform.
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to accelerate cell therapy development.
Kytopen and Aldevron collaborate to enhance cell therapy manufacturing using CRISPR-mediated engineering.
Kytopen expands its partnership into Europe through an agreement with T-CURX.
Kytopen reports progress in engineering monocyte-derived macrophages for therapeutic applications.
A study by Charles River shows superior performance of Flowfect Tx™ in gene editing of T cells.
Kytopen appoints new board of directors as part of its commercial expansion of the Flowfect Tx® platform.
Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to accelerate cell therapy development.
Kytopen and Aldevron collaborate to enhance cell therapy manufacturing using CRISPR-mediated engineering.
Kytopen expands its partnership into Europe through an agreement with T-CURX.
Kytopen reports progress in engineering monocyte-derived macrophages for therapeutic applications.
A study by Charles River shows superior performance of Flowfect Tx™ in gene editing of T cells.